Pharmaceutical Technology, Trends in Formulation, October 2022

Patient centricity is driving change in drug discovery and development, leading to a a new dawn in therapeutics.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.

How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.

The authors discuss the differences in mechanism of activation of N-nitrosamides versus N-nitrosamines and the fact that they should not be treated the same.

The author discusses some new applications of TPGS in the pharmaceutical field that should see this versatile excipient retain its place in the drug formulators toolbox.